Form 4: OnKure CEO Sells Shares for Tax Obligations

OnKure Therapeutics CEO Nicholas Saccomano sold 88 shares of Class A Common Stock on September 22, 2025, to cover tax withholding obligations related to RSU vesting.

Summary

• Nicholas A Saccomano, President and CEO, and a Director of OnKure Therapeutics, Inc. (OKUR), reported a transaction.
• On September 22, 2025, Saccomano disposed of 88 shares of Class A Common Stock.
• The shares were sold at a weighted average price of $2.6235 per share, with trades ranging from $2.60 to $2.645.
• This sale was automatic and executed to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs), as per the Issuer's 2023 RSU Equity Incentive Plan.
• Following this transaction, Saccomano beneficially owns 3,506 shares of Class A Common Stock, some of which are RSUs representing a contingent right to receive one share each.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary sale for tax purposes related to RSU vesting, which is a common occurrence for executives. It does not indicate any positive or negative sentiment regarding the company's performance or outlook.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

Insider transactions, particularly those related to tax withholding upon RSU vesting, are common occurrences in publicly traded companies. They typically do not reflect a discretionary decision by the insider regarding the company's future prospects but rather a mandatory event tied to compensation plans.

Stakeholder Impact

• Shareholders: The impact on shareholders is minimal due to the small number of shares involved and the non-discretionary nature of the sale. It does not signal a change in management's confidence or company fundamentals.

Key Dates

Recommendation

The reported transaction is a routine, non-discretionary sale of a small number of shares by the CEO to cover tax liabilities arising from RSU vesting. This does not indicate a change in management's outlook or the company's fundamentals, thus a 'hold' recommendation is appropriate as there is no new information to alter an existing investment thesis.

Keywords

OnKure Therapeutics, OKUR, Form 4, Insider Transaction, Stock Sale, RSU Vesting, Tax Withholding, Nicholas Saccomano